Treatment of hepatitis B e antigen-negative patients
Tóm tắt
Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) occurs at the late phase in hepatitis B virus (HBV) infection’s natural history. The disease is characterized by progressive liver damage due to variants with mutations in the precore/core promoter region that reduce or abolish HBeAg expression. Chronic HBeAg-negative disease’s prognosis is poor, with only rare incidences of spontaneous remission. Recent studies in Europe, Asia, and the United States all have reported an increased prevalence of HBeAg-negative and a decreased prevalence of HBeAg-positive chronic hepatitis; this may be related to increased awareness, decrease in new HBV infections, and aging of existing carriers. The end point of therapy for HBeAg-negative CHB patients is difficult to assess. In most studies, HBV DNA suppression and normalization of serum alanine aminotransaminase levels have been used to indicate therapeutic response. Six drugs currently are licensed for the treatment of CHB infection. These are the immunomodulatory agents (conventional interferon-α-2b and pegylated interferon-α-2a) and the nucleoside/nucleotide analogues (lamivudine, adefovir dipivoxil, entecavir, and telbivudine). Sustained treatment response rates generally are poor due to the high probability of relapse, particularly following nucleoside/nucleotide analogue therapy. As not all patients can tolerate or will respond to interferon-based therapy, maintenance therapy with nucleoside/nucleotide therapy is the alternative. However, this latter approach can lead to development of viral resistance and long-term safety concerns.
Tài liệu tham khảo
Maynard JE, Kane MA, Alter MJ, et al.: Control of hepatitis B by immunization: global perspective. In Viral Hepatitis and Liver Disease. Edited by Zuckerman AJ. New York: Alan R. Liss, Inc.; 1988:967–969.
Beasley RP, Hwang LY, Lin CC, et al.: Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 1981, 318:1129–1133.
Wu PC, Fang JW, Lai CL, et al.: Hepatic expression of hepatitis B virus genome in chronic hepatitis B virus infection. Am J Clin Pathol 1996, 105:87–95.
Carman WF, Jacyna MR, Hadziyannis S, et al.: Mutation preventing formation of HB e antigen in patients with chronic hepatitis B infection. Lancet 1989, 2:588–591.
Chen DS: Hepatitis B virus infection, its sequelae, and prevention in Taiwan. In Neoplasm of the Liver. Edited by Okuda K, Ishak KG. Tokyo: Springer-Verlag; 1987:71–80.
Hui CK, Leung N, Yuen ST, et al.: Natural history and disease progression in Chinese chronic hepatitis B patients in the immune-tolerant phase. Hepatology 2007, 46:395–401.
Beasley RP, Trepo C, Stevens CE, et al.: The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977, 105:94–98.
Hui CK, Cheung WW, Zhang HY, et al.: Kinetics and risk of de novo hepatitis B infection in HBsAg negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006, 131:59–68.
Chen YC, Sheen IS, Chu CM, et al.: Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002, 123:1084–1089.
Liaw YF, Chu CM, Su IJ, et al.: Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983, 84:216–219.
Hsu HC, Su IJ, Lai MY, et al.: Biologic and prognostic significance of hepatocyte hepatitis B core antigen expressions in the natural course of chronic hepatitis B virus infection. J Hepatol 1987, 5:45–50.
Fattovich G: Natural history and prognosis of hepatitis B. Semin Liv Dis 2003, 23:47–58.
Iloeje UH, Yang HI, Su J, et al.: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678–686.
Liaw YF, Tai DI, Chu CM, et al.: The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988, 8:493–496.
Beasley RP: Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988, 61:1842–1856.
Hui CK, Cheung WW, Zhang HY, et al.: Kinetics and risk of de novo hepatitis B infection in HBsAg negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006, 131:59–68.
Brunetto MR, Oliveri F, Coco B, et al.: Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002, 36:263–270.
Chu CJ, Hussain M, Lok AS: Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002, 36:1408–1415.
Hadziyannis S, Bramou T, Alexopoulou A, et al.: Immunopathogenesis and natural course of anti-HBe-positive chronic hepatitis with replicating B virus. In Viral Hepatitis and Liver Disease. Edited by Hollinger FB, Lemon SM, Margolis HS. Baltimore: Williams & Wilkins; 1992:673–676.
Bonino F, Rosina F, Rizzetto M, et al.: Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986, 90:1268–1273.
Naoumov NV, Portmann BC, Tedder RS, et al.: Detection of hepatitis B virus antigens in liver tissue. A relation to viral replication and histology in chronic hepatitis B infection. Gastroenterology 1990, 99:1248–1253.
Hsu YS, Chien RN, Yeh CT, et al.: Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35:1522–1527.
Funk ML, Rosenberg DM, Lok AS: World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepatol 2002, 9:52–61.
Iloeje UH, Yang HI, Su J, et al.: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678–686.
Chen CJ, Yang HI, Su J, et al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65–73.
de Franchis R, Hadengue A, Lau G, et al.: EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003, 39(Suppl 1):S3–S25.
Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45:507–539.
Papatheodoridis GV, Hadziyannis SJ: Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepatitis 2001, 8:311–321.
Manesis EK, Hadziyannis SJ: Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001, 121:101–109.
Janssen HL, Schalm SW, Berk L, et al.: Repeated courses of alpha-interferon for treatment of chronic hepatitis B. J Hepatol 1993, 17(Suppl 3):S47–S51.
Brook MG, Karayiannis P, Thomas HC: Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictor factors. Hepatology 1989, 10:761–763.
Schiff ER: Treatment algorithms for hepatitis B and C. Gut 1993, 34(Suppl 2):S148–S149.
Kao JH, Wu NH, Chen PJ, et al.: Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000, 33:998–1002.
Marcellin P, Lau G, Bonino F, et al.: Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206–1217.
Schalm SW, de Man RA, Heijtink RA, Niesters HG: New nucleoside analogues for chronic hepatitis B. J Hepatol 1995, 22(Suppl 1):52–56.
Dienstag JL, Perillo RP, Schiff ER, et al.: A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995, 333:1704–1705.
Tassopoulos NC, Volpes R, Pastore G, et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999, 29:889–896.
Allen MI, Deslauriers M, Andrews CW, et al.: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27:1670–1677.
Lok AS, Lai CL, Leung N, et al.: Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125:1714–1722.
Melagari M, Scaglioni PP, Wanda JR: Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998, 27:628–633.
Ono-Nita SK, Kato M, Shiratori Y, et al.: YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vivo full-length viral DNA transfection. Hepatology 1999, 29:939–945.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003, 348:800–807.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005, 352:2673–2681.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743–1751.
Locarnini S, Qi X, Arterburn S, et al.: Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil therapy for patients with chronic hepatitis B. J Hepatol 2005, 42(Suppl 1):17.
Lai CL, Shouval D, Lok AS, et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011–1020.
Colonno RJ, Rose RE, Pokornowski K, et al.: Assessment at three years shows high barrier to resistance is maintained in entecavir treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients [abstract]. Hepatology 2006, 44:229A.
Sherman M, Yurdaydin C, Sollano J, et al.: Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006, 130:2039–2049.
Lai CL, Gane E, Chao-Wei H, et al.: Two-year results from the GLOBE Trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine vs. lamivudine [abstract]. Hepatology 2006, 44(Suppl):222A.